Tango Therapeutics president Crystal Adam sells $798,908 in stock
Crystal Adam, President of Research & Development at Tango Therapeutics, sold 27,000 shares of company common stock for $798,908 after exercising stock options. The transactions were conducted under a pre-arranged trading plan, with shares sold in two blocks at weighted average prices of $29.3424 and $30.2464. Following these sales, Adam directly holds 115,743 shares and 314,040 derivative shares in stock options.
Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised stock options for 27,000 shares at $5.20 per share and subsequently sold all 27,000 shares in open-market transactions. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted-average prices between approximately $29 and $30 per share. Following these transactions, Adam directly holds 142,743 shares of Tango Therapeutics common stock.
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com
This article reports on a Form 4 filing for Tango Therapeutics Inc (TNGX) on July 2nd. It notes the company's stock performance (TNGX +2.54%) within the context of broader market movements and several other financial data points. The article is very brief and primarily serves as a notification of the filing.
Price to book forward of Tango Therapeutics, Inc. – NASDAQ:TNGX
This article focuses on the "Price to book forward" metric for Tango Therapeutics, Inc. (NASDAQ:TNGX). It appears to be a financial data snippet from TradingView, providing an overview of the company's financial information within their platform. The content primarily shows the navigation and various features available on TradingView, rather than detailed financial analysis.
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Tango Therapeutics is a key player in precision oncology, focusing on MTAP-deleted cancers with therapies like vopimetostat (TNG462) and TNG456. The company is using a synthetic-lethality approach and combination therapies, particularly for pancreatic, lung, and brain tumors, and has shown promising early results in pancreatic cancer. While the stock currently holds a Zacks Rank #3 (Hold), upcoming clinical data in 2026 will be crucial for determining its long-term investment viability.
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Tango Therapeutics (TNGX) has seen a dramatic rally in 2026 due to promising clinical progress with its drug vopimetostat, particularly for MTAP-deleted, RAS-mutant pancreatic cancer. Despite this, the company faces risks as it is still clinical-stage with no product revenues and relies heavily on future clinical execution and regulatory approvals. The significant stock appreciation has also created a premium valuation, leading to caution among investors regarding continued momentum without further strong clinical data.
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Tango Therapeutics (TNGX) is entering a crucial period, with its stock outlook primarily tied to the success of vopimetostat and key clinical updates expected in 2026. The company's strategy focuses on MTAP-deleted cancers with a narrowed pipeline, leading to higher concentration risk. While early pancreatic cancer data for vopimetostat have been promising, investors will be looking for broader efficacy and further regulatory feedback to solidify the stock's future.
Tango Therapeutics (TNGX) Enters Russell Growth Indexes and Adds Biopharma Veteran Azelby to Board
Tango Therapeutics (TNGX) has been included in several Russell Growth benchmarks and simultaneously removed from Value and Microcap indexes in late June 2026, signaling a market perception shift towards it as a high-growth, high-risk biotech. Concurrently, the company appointed biopharma veteran Robert Azelby to its board, adding commercialization expertise as it progresses its precision-oncology pipeline. This repositioning highlights the company's focus on its growth-oriented cancer drug development and potential late-stage advancements.
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark
Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. This news comes alongside other index adjustments for the company, including being dropped from several Russell Value and Microcap indices. The stock has seen significant price changes, including a +3.46% change on Jun. 29, and recent analyst upgrades with higher price targets.
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark
Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 2000 Growth Benchmark. This news comes alongside several other announcements regarding the company's inclusion and exclusion from various Russell indices, including being dropped from the Russell Small Cap Comp Value Benchmark, Russell 3000 Value Benchmark, and Russell Microcap Index. The company is a clinical-stage biotechnology firm focused on developing precision medicines for cancer.
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark
Tango Therapeutics, Inc. (NasdaqGM:TNGX) has been removed from the Russell Small Cap Comp Value Benchmark. This decision by S&P Capital IQ was announced on June 29, 2026, at 06:16 am EDT. Concurrently, the company was also added to the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark.
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000 Growth Benchmark
Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 3000 Growth Benchmark, as announced on June 28, 2026. This inclusion is part of several recent index adjustments, which also saw the company added to the Russell 2500 Growth Benchmark and dropped from other benchmarks like the Russell 3000 Value Benchmark. Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for cancer treatment.
Tango Therapeutics (TNGX) Could Be 64% Below Fair Value As It Adds Robert Azelby
Tango Therapeutics (TNGX) recently appointed Robert Azelby to its Board of Directors, as it advances its investigational PRMT5 inhibitor vopimetostat. The company's share price has shown strong momentum, with significant returns over the last year. Simply Wall St's DCF model estimates a fair value of $51.54 per share, suggesting the stock is currently undervalued at $31.47, though its high P/B ratio indicates potential valuation risk.
Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark
Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been removed from the Russell 2500 Value Benchmark, as reported by S&P Capital IQ on June 28, 2026. This exclusion is part of several benchmark adjustments for the company around the same date, including additions to growth benchmarks and removals from various other Russell indices. The biotechnology company focuses on developing precision medicines for cancer.
Enterprise value to revenue forward of Tango Therapeutics, Inc. – NASDAQ:TNGX
This article provides the enterprise value to revenue forward for Tango Therapeutics, Inc. (NASDAQ: TNGX) via TradingView. It highlights the company's financial data as part of its market overview within the Health Technology and Biotechnology sectors. The content presented is primarily a financial data point without further analysis or discussion.
Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX
This article focuses on the enterprise value to EBITDA forward for Tango Therapeutics, Inc. (NASDAQ: TNGX), as presented by TradingView. It appears to be a financial data snippet rather than a comprehensive article, indicating a focus on a specific valuation metric for the company.
Enterprise value to EBIT forward of Tango Therapeutics, Inc. – NASDAQ:TNGX
This article displays an enterprise value to EBIT forward metric for Tango Therapeutics, Inc. (NASDAQ:TNGX) as observed on TradingView. The page provides financial information for the company, indicating the market was closed at the time of viewing. It also highlights that the data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr.
Jefferies upgrades Tango Therapeutics stock rating on cancer trial data
Jefferies upgraded Tango Therapeutics (NASDAQ: TNGX) to Buy from Hold and raised its price target to $60.00 from $27.00, citing strong early progression-free survival data from a cancer trial. The firm's analysis of pancreatic ductal adenocarcinoma data suggests a median progression-free survival of approximately 13 months, significantly higher than the 8.1 months observed with daraxonrasib. The upgrade projects substantial peak revenues from first-line and second-line therapies, with further data expected later in 2026.
Price to sales forward of Tango Therapeutics, Inc. – NASDAQ:TNGX
This page provides information on the "Price to sales forward" metric for Tango Therapeutics, Inc. (NASDAQ: TNGX). It is an excerpt from a financial data platform, likely TradingView, focusing on the company's financial overview within the biotechnology sector. The content itself seems to be a placeholder or selection from a larger financial report.
Will Tango Therapeutics’ New Board Hire Reframe Its Commercialization Strategy for Vopimetostat (TNGX)?
Tango Therapeutics recently appointed Robert Azelby, a biopharma veteran with extensive oncology commercialization experience, to its Board of Directors. This appointment comes as Tango advances its investigational PRMT5 inhibitor, vopimetostat, for MTAP-deleted pancreatic cancer and is preparing for potential late-stage development and commercialization. While Azelby's expertise is valuable for future commercialization, near-term catalysts for TNGX stock will still be clinical readouts and clarity on trial design.
Form 4 Tango Therapeutics Inc For: 23 June By Investing.com
This article announces the filing of a Form 4 for Tango Therapeutics Inc. on June 23 by Investing.com. It is a brief administrative notice indicating an insider transaction for the company. The content includes boilerplate navigation and market data, but the core message is the Form 4 filing.
Form 8K Tango Therapeutics Inc For: 23 June By Investing.com
This article announces that Tango Therapeutics Inc. filed a Form 8K for June 23, 2026. It includes stock market data for TNGX, which was up 2.75% at the time, and provides various global market indices and commodity prices. The content appears to be a standard financial market update from Investing.com.
New Tango Therapeutics (TNGX) director Robert Azelby files initial Form 3
Robert Azelby, a new director at Tango Therapeutics (TNGX), has filed an initial Form 3, which is a statement of beneficial ownership. This filing indicates his new role as a director but does not report any current stock transactions or holdings for him. A Form 3 serves as a baseline for future reporting of insider transactions.
Form 8K Tango Therapeutics Inc For: 23 June By Investing.com
This article announces the filing of a Form 8K by Tango Therapeutics Inc. for June 23. It includes a brief mention of the company's stock symbol (TNGX) and its performance on that date. The content is primarily a placeholder for more detailed financial news, surrounded by general market data and other news headlines.
Biotech veteran Robert Azelby joins Tango Therapeutics (TNGX) board as company advances vopimetostat
Tango Therapeutics has expanded its Board of Directors to seven members, appointing biopharmaceutical executive Robert Azelby as a Class II director. Mr. Azelby, with over three decades of industry experience including oncology commercialization, will serve on the Compensation and Nominating and Corporate Governance Committees. His appointment comes as Tango advances vopimetostat, an investigational PRMT5 inhibitor targeting MTAP-deleted cancers, towards potential late-stage development.
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics, a clinical-stage biotechnology company, has appointed Robert Azelby to its Board of Directors. Azelby brings over 30 years of biopharmaceutical leadership experience, particularly in oncology commercialization and corporate governance. His appointment is strategic as Tango advances vopimetostat, an investigational PRMT5 inhibitor for pancreatic cancer, towards potential late-stage development and commercialization.
Tango Therapeutics Company Profile & Introduction
This article provides a company profile and introduction to Tango Therapeutics. As a content cleaning and metadata extraction specialist, I cannot generate further summary details without the actual content of the article.
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics, a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings over three decades of leadership experience in the biopharmaceutical industry, particularly in oncology commercialization and corporate strategy. His expertise will be crucial as Tango advances its investigational PRMT5 inhibitor, vopimetostat, towards late-stage development for pancreatic cancer.
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics (NASDAQ: TNGX) has appointed Robert Azelby to its Board of Directors, bringing over three decades of biopharmaceutical industry experience, particularly in oncology commercialization and corporate strategy. This appointment strengthens the board as Tango Therapeutics advances vopimetostat, an investigational PRMT5 inhibitor for pancreatic cancer, towards late-stage development and potential market entry. Azelby's expertise is expected to be invaluable in guiding the company's clinical and strategic priorities for its precision cancer medicines pipeline.
Tango Therapeutics appoints Robert Azelby to board of directors By Investing.com
Tango Therapeutics has appointed Robert Azelby to its board of directors, bringing over 30 years of biopharmaceutical industry experience as the company advances its investigational PRMT5 inhibitor, vopimetostat, for pancreatic cancer. Despite a significant 442% return over the past year, the stock is considered overvalued, though the company possesses a strong balance sheet. Recent financial activities include a $600 million stock offering and analyst upgrades following positive Phase 1 trial results for vopimetostat in combination treatments.
Tango Therapeutics appoints Robert Azelby to board of directors
Tango Therapeutics (NASDAQ:TNGX) has appointed Robert Azelby to its board of directors, bringing over 30 years of biopharmaceutical industry experience, particularly in oncology commercialization and corporate strategy. This appointment comes as the company advances its investigational PRMT5 inhibitor, vopimetostat, for pancreatic cancer. Despite a significant 442% return over the past year, TNGX shares recently pulled back, and InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value estimate.
Tango Therapeutics taps oncology veteran Robert Azelby for its board
Tango Therapeutics (NASDAQ: TNGX) has appointed oncology veteran Robert Azelby to its Board of Directors. Azelby brings over 30 years of leadership experience in oncology commercialization, corporate strategy, and governance. His appointment comes as Tango Therapeutics advances vopimetostat, an investigational PRMT5 inhibitor, towards potential late-stage development for MTAP-deleted pancreatic cancers.
Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics has appointed Robert Azelby to its Board of Directors, bringing extensive leadership experience in the biopharmaceutical industry, particularly in oncology commercialization, corporate strategy, and board governance. His appointment is expected to provide valuable expertise as Tango advances its investigational PRMT5 inhibitor, vopimetostat, towards late-stage development for pancreatic cancer. Azelby's background includes leadership roles at Eliem Therapeutics, Alder BioPharmaceuticals, Juno Therapeutics, and Amgen, and he currently serves on several other company boards.
Tango Therapeutics files for $500 million common stock offering
Tango Therapeutics has filed for a $500 million common stock offering. This move indicates the company's intention to raise a significant amount of capital through the sale of its shares. The filing underscores a strategic financial decision to potentially fund future operations, research, or expansion.
Tango Therapeutics stock hits all-time high at 33.19 USD By Investing.com
Tango Therapeutics stock reached an all-time high of $33.19, reflecting a 582.29% increase over the past year, though InvestingPro analysis suggests it may be overvalued. The company recently announced two stock offerings totaling $1.1 billion and received raised price targets and continued "Buy" ratings from analysts following positive Phase 1 trial results for its cancer therapy.
Tango Therapeutics stock hits all-time high at 33.19 USD
Tango Therapeutics stock has reached an all-time high of $33.19, reflecting a 582.29% increase over the past year, indicating strong investor confidence despite being considered overvalued by InvestingPro. This surge follows recent strategic stock offerings and positive Phase 1 trial results for its drug combination, leading to increased price targets from analysts. The company's performance highlights its growing presence in the biotechnology sector.
TNGX (Nasdaq: TNGX) affiliate files Form 144 to sell 3.5M shares
An affiliate of Tango Therapeutics (Nasdaq: TNGX), NEXTECH CROSSOVER I SCSP, has filed a Form 144 to report the planned sale of 3.5 million shares of common stock. These sales are spread across three transactions from June 11-15, 2026, totaling $105,052,300 in gross proceeds. The filing indicates these shares are related to previous private placements and outlines the regulatory intent to sell.
Tango Therapeutics (TNGX) Stock Could Be 39% Below Fair Value After Trial Data And Offering
Tango Therapeutics (TNGX) has gained significant attention following positive Phase 1/2 vopimetostat trial data and a US$600 million equity offering, leading to a 260.13% year-to-date share price return. Despite an apparently high Price-to-Book ratio of 11.9x compared to industry averages, Simply Wall St's Discounted Cash Flow (DCF) model suggests the stock's fair value is $52.76 per share, indicating it could be undervalued at its current price of $32.16. The article highlights the discrepancy between traditional P/B valuation and DCF analysis for this unprofitable, high-growth biotech.
Tango Therapeutics Inc (TNGX) Institutional Confidence
Tango Therapeutics Inc (TNGX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 123.32%, up 24.30% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 568.45K shares.
Tango Therapeutics Inc (TNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Tango Therapeutics Inc (TNGX) has an earnings forecast score of 8.17, ranking 157 out of 388 in its industry. Analysts set an average price target of $13.50 for TNGX, with predictions ranging from $11.00 to $15.00, and most analysts recommend a "Buy" rating. The company's EPS for the previous quarter was -$0.29, outperforming the market expectation of -$0.32.
Tango Therapeutics (TNGX) Is Up 6.4% After $600 Million Raise Backs Vopimetostat Combo Data
Tango Therapeutics (TNGX) recently completed a US$600 million equity offering following promising Phase 1/2 data for its PRMT5 inhibitor vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors for hard-to-treat cancers. This significant raise and positive clinical trial results are expected to strengthen Tango's oncology pipeline, particularly with plans to advance vopimetostat into Phase 3 trials. While the fresh capital improves the company's financial position for future trials, existing shareholders have experienced dilution after a substantial share price run, shifting investment risks towards clinical execution and regulatory feedback.
[144] Tango Therapeutics, Inc. SEC Filing
Tango Therapeutics, Inc. (TNGX) filed a Form 144 on June 11, 2026, indicating proposed sales of its Common Stock with a total figure of $51,523,582.08. The filing details multiple share lots, including 1,625,739 shares from a stock option exercise and 165,987 restricted shares. It also notes a recent sale by Daniella Beckman of 4,446 shares for $133,380.00, with Morgan Stanley Smith Barney LLC listed as the broker.
Tango Therapeutics (TNGX) raises ~$566.5M via 18.17M shares and pre-funded warrants
Tango Therapeutics (TNGX) announced it is offering 18.17 million shares of common stock and pre-funded warrants to purchase an additional 1.83 million shares, at a public offering price of $30.00 per share. The company expects to raise approximately $566.5 million in net proceeds, which will be allocated towards general corporate purposes including research and development, pivotal trial expenses, and potential commercialization efforts. This significant capital raise follows recent positive clinical data, including a 92% objective response rate for its vopimetostat combination therapy in pancreatic cancer.
Tango Therapeutics Announces Major Underwritten Equity Offering
Tango Therapeutics announced a major underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $566.5 million. This capital infusion is expected to extend the company's cash runway into 2030, supporting its oncology research and development, pivotal trials, and commercialization efforts. While strong in technical momentum and pipeline progress, the company faces challenges with weak financial fundamentals and ongoing losses, leading to a "Neutral" rating from TipRanks’ AI Analyst, Spark.
Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted
Tango Therapeutics has priced an equity offering of approximately $566.5 million, selling shares at $30.00 each and pre-funded warrants at $29.999. The underwriters, J.P. Morgan Securities and Leerink Partners, have a 30-day option for additional shares. The company intends to use the net proceeds for research and development, a pivotal trial, commercialization preparation, and general corporate purposes, with closing anticipated on June 11, 2026.
Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering
Tango Therapeutics (NASDAQ: TNGX) has priced an underwritten public offering of common stock and pre-funded warrants, expecting net proceeds of approximately $566.5 million. This capital infusion is intended to fund operating expenses, capital expenditure requirements, research and development, and pivotal trial expenses into 2030. The offering includes 18,166,667 shares of common stock at $30.00 each and pre-funded warrants for up to 1,833,395 shares at $29.999 each, with a 30-day option for underwriters to purchase additional shares.
Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates
Tango Therapeutics (TNGX) stock has seen a significant surge due to positive early clinical trial results for its pancreatic cancer drug, vopimetostat, especially when combined with Daraxonrasib. The company's shares jumped by as much as 53% and even hit an all-time high, with analysts calling the trial data "groundbreaking." Additionally, investment firm RTW Investments significantly increased its stake in Tango Therapeutics, adding over 11 million shares.
Tango Therapeutics prices $600 million stock offering
Tango Therapeutics (NASDAQ:TNGX) has announced the pricing of a public offering expected to raise $600 million through the sale of common stock and pre-funded warrants. The offering price is set at $30.00 per share for common stock and $29.999 for pre-funded warrants, with the transaction anticipated to close around June 11, 2026. This financial move follows a significant 606% stock surge over the past year, though the company remains unprofitable.
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
Tango Therapeutics, Inc. has announced the pricing of an upsized public offering of common stock and pre-funded warrants, expected to generate approximately $600 million before deductions. The offering includes 18,166,667 shares of common stock at $30.00 per share and 1,833,395 pre-funded warrants at $29.999 each. J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint bookrunning managers, with the offering anticipated to close around June 11, 2026.
Tango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Tango Therapeutics announced the pricing of an underwritten offering aiming to raise approximately $600 million through the sale of 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants for an additional 1,833,395 shares at $29.999 per warrant. The offering is expected to close on June 11, 2026, and includes a 30-day option for underwriters to purchase up to 3 million additional shares. This capital raise, managed by J.P. Morgan and Leerink Partners, will support the company's development of precision cancer therapies.
